Condition
Liver Diseases
Locations
United States
Start date
04/06/2024
Identifiers
Trial ID
NN7535-7703,
NCT number NCT06336018,
Eudract number Not Available
NCT number NCT06336018,
Eudract number Not Available
Summary
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.
Trial Overview:
Treatment
DRUG: Etavopivat
Study type
INTERVENTIONAL
Trial duration
Jun 04 2024 - Sep 04 2025
Participants
48
Phase
I
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.